 | Up a level |
Carneiro, A., Amaral, T. M. S., Brandao, M., Scheffler, M., Bol, K., Ferrara, R., Jalving, M., Lo Russo, G., Marquez-Rodas, I., Matikas, A., Mezquita, L., Morgan, G., Onesti, C. E., Pilotto, S., Saloustros, E. and Trapani, D. (2020). Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Ann. Oncol., 31. S. S1196 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Eiger, D., Maurer, C., Brandao, M., Aftimos, P. G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M. and Buisseret, L. (2020). First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann. Oncol., 31. S. S386 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Maurer, C., Agostinetto, E., Ameye, L., Lambertini, M., Martel, S., Ponde, N. F., Brandao, M., Poggio, F., Ferreira, A. R., Schiff, R., De Angelis, C., Gelber, R. D., Dent, S., Thomssen, C., Piccart, M. and de Azambuja, E. (2022). Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial. Ann. Oncol., 33. S. S154 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041